Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04865029 · ClinicalTrials.gov registry record · Phase 2
Estradiol and Progesterone in Hospitalized COVID-19 Patients
A Phase 2 study, sponsored by Tulane University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04865029 is a Phase 2 study that was terminated before completion, run by Tulane University. The registered enrollment target is 10 participants.
The verdict
NCT04865029, a Phase 2 study, was terminated before completion, sponsored by Tulane University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine to what extent a short systemic steroid therapy with estradiol and progesterone, administered early to hospitalized and confirmed COVID-19 positive patients of both sexes in addition to standard of care (SOC) can reduce the severity of symptoms and outcomes compared to SOC alone.
Interventions
- OTHER Placebo injection and placebo pill
- DRUG Estradiol Cypionate 5 mg/ml
- DRUG Progesterone 200 mg Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-07-22 |
| Est. Completion | 2022-01-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04865029
The ClinicalTrials.gov registry entry for NCT04865029 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tulane University, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo injection and placebo pill is the first listed.
NCT04865029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04865029 about?
NCT04865029 is a clinical study titled "Estradiol and Progesterone in Hospitalized COVID-19 Patients". The purpose of this study is to determine to what extent a short systemic steroid therapy with estradiol and progesterone, administered early to hospitalized and confirmed COVID-19 positive patients of both sexes in addition to standard of care (SOC) can reduce the severity of symptoms and outcomes ...
What is the current status of trial NCT04865029?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2021-07-22. Estimated completion is 2022-01-25.
What interventions are being tested in trial NCT04865029?
The interventions under investigation include: Placebo injection and placebo pill (OTHER), Estradiol Cypionate 5 mg/ml (DRUG), Progesterone 200 mg Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT04865029?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.